Progress, Potential, and Possibilities Podcast / Show · 2026-05-15 · 25 min
Send us Fan Mail For more than 30 years, small cell lung cancer has remained one of the most aggressive and difficult-to-treat cancers - marked by rapid progression, high relapse rates, and very few meaningful advances. But that may finally be starting to change. Today, we’re joined by Dr. Angela Coxon, Ph.D., Vice President of Research and Development at Amgen ( ), where she helps lead the development of next-generation therapies aimed at tackling exactly these kinds of challenges. Her work spans discovery research, translational medicine, and molecular oncology - bridging the gap between early scientific insight and real-world impact for patients. If you’ve been following the show, you may remember our conversation with Amgen's Dr. Ryan Potts, where we explored the emerging concept of Induced Proximity - the idea that instead of simply blocking biology, we can design drugs that bring components together to create entirely new functions.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Putting the “Tech” in Biotech: An Unconventional Path to Building a Therapeutics Company, with Federico Paoletti, PhDBuilding Biotechs · on Immunotherapy72 / 100
#139 Justin Coombs, COO at AusHealth on Revolutionising Healthcare Through InnovationCreating Synergy Podcast · on Immunotherapy71 / 100
This Just In Radio: CancerX 2026 with Dr. John Cleveland and Xavier AvatThis Just In Radio Show · on Immunotherapy68 / 100
Inside the Physician Decisions That Make Oncology Trials Safer & SmarterLife Science Success · on Immunotherapy54 / 100Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 10055 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100How Regenerative Medicine Is Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, MD, PhD - Chief Scientific Officer and Co-Founder - Conexeu Sciences